Research Letter

Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab

Author Affiliation(s)



1. Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799. doi:10.1111/jdv.14386 2. Maliyar K, Crowley EL, Rodriguez-Bolanos F, O'Toole A, Gooderham MJ. The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review. J Cutan Med Surg. 2019;23(4):428-435. doi:10.1177/1203475419836435 3. Miller AC, Holland TE, Cohen DJ. Treatment of acrodermatitis continua of hallopeau with ixekizumab. J Dermatolog Treat. 2021;32(1):117-119. doi:10.1080/09546634.2019.1628170 4. Narcisi A, Valenti M, Cortese A, et al. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study. Dermatol Ther. 2022;35(2):e15228. doi:10.1111/dth.15228 5. Husson B, Barbe C, Hegazy S, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2020;34(10):2330-2338. doi:10.1111/jdv.16265 6. Gargiulo L, Pavia G, Ibba L, et al. Generalized Pustular Psoriasis and Plaque Psoriasis Successfully Treated With Ixekizumab. Clin Exp Dermatol Ther. 2022; 7: 183. doi: 10.29011/2575-8268.100183. Published online ahead of print.

Send mail to Author

Send Cancel